Richard Hennings is C-suite biopharma entrepreneur with +30 years global experience, developing and commercializing innovative therapies.
Richard has diverse organizational knowledge from roles within top ten global pharmaceuticals & microcap biotech start-ups.
He is an accomplished leader, building organisational capability through cross-functional team leadership & influential relationships with board of directors, joint venture partners and external patient/ medical associations. His experience spans early-stage portfolio strategy development, fundraising & commercial execution.
Richard recently served as Chief Commercial Officer at Synairgen, previously holding commercial leadership roles at Gilead, Novartis, AstraZeneca & Verona Pharma, where he supported a $200M Ph 3 fund raise for Ohtuvayre®. During his Gilead tenure Richard led the expansion of respiratory & anti-viral product portfolios in the EU & US markets, launching inhaled Cayston® for Cystic Fibrosis & HIV treatment Stribild®.